Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Agios Pharmaceuticals (AGIO) with a Buy rating and $58 price target The firm views the company’s lead asset mitapivat as a “pipeline within a drug” and expects three approved indications by the end of 2026. The analyst is confident in the upcoming Phase 3 data from the RISE UP study in late 2025. Current Agios stock levels present an attractive buying opportunity as hepatocellular injury concerns are overdone, the analyst tells investors in a research note.